The partners will adapt Eukarÿs' C3P3 engineered enzyme tech to work with adeno-associated virus vectors to boost biomanufacturing yields.
Genethon & Eukarÿs enter strategic partnership to develop a breakthrough technology to reduce the biomanufacturing cost of gene therapies: Evry, France Friday, January 24, 2025, ...
The companies will focus on advancing AXV-101, with which they hope to treat retinal dystrophy by targeting mutations in the BBS1 gene.
The goal is to treat familial dysautonomia patients with a single injection.
Additional details on the meeting can be found at the WORLD Symposium website. About Spur Therapeutics Spur Therapeutics is a clinical-stage biotechnology company focused on developing life-changing ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/100.BGpatWXx.js ...
New Vericheck ddPCR Empty-Full Capsid Kits for AAV Serotypes 2 and 8 Provide Precise Measurement of Viral Titer and Capsid ...
A team of researchers at The Hormel Institute, University of Minnesota, led by Associate Professor Vijay Reddy, PhD, published a paper in the leading journal Nature Communications. The paper, ...
Explore the role of preclinical MRI in studying neurological diseases, with a focus on advanced cellular and molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback